PSMA4
ENSG00000041357
Target class
Unclassified protein
Chromosome
15
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- PSMA4
- Gene name
- Proteasome 20S subunit alpha 4
- Gene symbol
- PSMA4
- Protein name
- Proteasome subunit alpha type-4 (Macropain subunit C9) (Multicatalytic endopeptidase complex subunit C9) (Proteasome component C9) (Proteasome subunit L) (Proteasome subunit alpha-3) (alpha-3)
- HC9
- HsT17706
- Gene biotype
- Protein coding
- Gene family
- Proteasome
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 77.16
- Tissue specificity (Gini)
- 0.235
- Tissue specificity (tau)
- 0.653
- KEGG gene identifiers
- hsa:5685
- Protein interaction confidence
- 0.922244
- Protein interaction partners
- 78
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 43 more, listed on the interactive page.
- End position
- 78552417
- Start position
- 78540089
- Chromosome
- 15
- Strand
- Forward
- Cytoplasm . Nucleus . Note=Translocated from the cytoplasm into the nucleus following interaction with AKIRIN2, which bridges the proteasome with the nuclear import receptor IPO9 (PubMed:34711951). Colocalizes with TRIM5 in the cytoplasmic bodies (By similarity). .
- Connecting piece
- Cytosol
- Flagellar centriole
- Mid piece
- Nucleoplasm
- Vesicles
- PubMed 12181345
- PubMed 34711951
- Tissue specificity (tau)
- 0.653266
- Expression inequality (Gini)
- 0.234986
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 77.16
- Testis
- 51.5
- Cells - Cultured fibroblasts
- 48.58
- Uterus
- 39.88
- Spleen
- 39.47
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes77.16
- Testis51.5
- Cells - Cultured fibroblasts48.58
- Uterus39.88
- Spleen39.47
- Cervix - Endocervix39.09
- Cervix - Ectocervix38.17
- Prostate37.54
- Lung37.14
- Colon - Sigmoid36.43
- Nerve - Tibial35.11
- Adipose - Subcutaneous34.73
- Small Intestine - Terminal Ileum34.43
- Esophagus - Mucosa34.33
- Artery - Coronary33.12
- Vagina33
- Bladder32.94
- Thyroid32.71
- Breast - Mammary Tissue32.43
- Esophagus - Muscularis31.79
- Fallopian Tube31.7
- Colon - Transverse31.48
- Artery - Tibial31.4
- Artery - Aorta31.13
- Esophagus - Gastroesophageal Junction31.05
And 29 more, listed on the interactive page.
- GO:0006979
- GO:0010498
- GO:0043161
- GO:0061136
- GO:0000502
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0005839
- GO:0019773
- GO:0070062
- GO:0005515
- GO:0140756
Related records
Trials (799)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (6)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Marizomib 20S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor